Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT095 CAR-T in advanced gastrointestinal tumors
NCT05515185Phase 1Unknown
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KT095 in gastrointestinal tumor and solid tumor, sponsored by First People's Hospital of Lianyungang City. Primary endpoints: Dose-limiting toxicity at 2 years and Maximum tolerable dose at 2 years. Status: unknown.
02
Drugs
KT095
03
Conditions
gastrointestinal tumorsolid tumor
Beyond the preview
Go deeper on NCT05515185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515185.